Covington Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Covington Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$32K	Hold	495	–	–	﹤0.01%	629
2022 Q2	$30K	Buy	495 +100	+25%	+$5.88K	﹤0.01%	640
2022 Q1	$25K	Hold	395	–	–	﹤0.01%	682
2021 Q4	$30K	Hold	395	–	–	﹤0.01%	611
2021 Q3	$44K	Hold	395	–	–	﹤0.01%	566
2021 Q2	$64K	Hold	395	–	–	﹤0.01%	507
2021 Q1	$48K	Hold	395	–	–	﹤0.01%	483
2020 Q4	$60K	Hold	395	–	–	﹤0.01%	441
2020 Q3	$33K	Hold	395	–	–	﹤0.01%	482
2020 Q2	$29K	Buy	395 +20	+5%	+$1.17K	﹤0.01%	495
2020 Q1	$16K	Sell	375 -200	-35%	-$10.3K	﹤0.01%	552
2019 Q4	$35K	Hold	575	–	–	﹤0.01%	513
2019 Q3	$24K	Hold	575	–	–	﹤0.01%	530
2019 Q2	$27K	Hold	575	–	–	﹤0.01%	508
2019 Q1	$21K	Hold	575	–	–	﹤0.01%	529
2018 Q4	$16K	Hold	575	–	–	﹤0.01%	574
2018 Q3	$26K	Buy	575 +200	+53%	+$10.5K	﹤0.01%	500
2018 Q2	$22K	Hold	375	–	–	﹤0.01%	535
2018 Q1	$17K	Buy	375 +175	+88%	+$7.22K	﹤0.01%	577
2017 Q4	$5K	Hold	200	–	–	﹤0.01%	742
2017 Q3	$4K	Buy	+200	New	+$3.63K	﹤0.01%	661

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Covington Capital Management's CRSP Position: Q3 2022 in Review

Covington Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2022 at 495 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Covington Capital Management first reported a position in CRSP in Q3 2017 and has held it in 21 quarters since. The position peaked at $64K in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Covington Capital Management held 495 shares of CRISPR Therapeutics worth $32K as of Q3 2022.
Covington Capital Management left its CRISPR Therapeutics share count unchanged in Q3 2022.
CRISPR Therapeutics made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #629 holding.
Covington Capital Management first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 21 quarters since.
Covington Capital Management's CRISPR Therapeutics position peaked at $64K in Q2 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.